欧林生物
(688319)
| 流通市值：62.55亿 | | | 总市值：62.64亿 |
| 流通股本：4.05亿 | | | 总股本：4.06亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 87,490,281.98 | 588,858,464.45 | 386,646,898.48 | 226,277,670.03 |
| 营业收入 | 87,490,281.98 | 588,858,464.45 | 386,646,898.48 | 226,277,670.03 |
| 二、营业总成本 | 103,562,135.21 | 569,996,827.89 | 379,815,023.64 | 244,503,957.28 |
| 营业成本 | 5,748,186.46 | 32,707,434.85 | 20,425,109.52 | 12,303,240.64 |
| 税金及附加 | 512,277.03 | 3,716,416.72 | 2,226,976.66 | 1,599,701.24 |
| 销售费用 | 41,886,928.76 | 302,899,962.16 | 185,241,304.11 | 102,821,367.26 |
| 管理费用 | 22,743,811.47 | 86,424,382.85 | 63,044,731.6 | 46,873,708.04 |
| 研发费用 | 29,123,911.81 | 134,233,724.19 | 99,399,717.64 | 75,288,312.43 |
| 财务费用 | 3,547,019.68 | 10,014,907.12 | 9,477,184.11 | 5,617,627.67 |
| 其中:利息费用 | 3,719,578.74 | 14,283,986.99 | 10,383,811.72 | 6,374,239.33 |
| 其中:利息收入 | 229,609.01 | 4,508,119.26 | 1,101,681.82 | 902,987.64 |
| 加:投资收益 | 70,592.05 | 855,559.79 | 500,625.69 | 178,893.35 |
| 资产处置收益 | - | -30,988.3 | - | - |
| 资产减值损失(新) | 1,271,436.02 | 2,936,350.79 | 5,074,024.15 | 5,410,956.23 |
| 信用减值损失(新) | 3,388,796.25 | -10,375,765.79 | -15,589,377.17 | -21,914,696.83 |
| 其他收益 | 4,297,791.76 | 9,063,439.56 | 3,702,801 | 2,807,191.33 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,043,237.15 | 21,310,232.61 | 519,948.51 | -31,743,943.17 |
| 加:营业外收入 | 1,703.81 | 1,140,439.08 | 1,044,193.66 | 1,041,527.85 |
| 减:营业外支出 | - | 146,971.33 | 116,871.33 | 16,756.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -7,041,533.34 | 22,303,700.36 | 1,447,270.84 | -30,719,171.37 |
| 减:所得税费用 | - | 6,583,013.04 | 1,530,181.21 | - |
| 六、净利润 | -7,041,533.34 | 15,720,687.32 | -82,910.37 | -30,719,171.37 |
| 持续经营净利润 | -7,041,533.34 | 15,720,687.32 | -82,910.37 | -30,719,171.37 |
| 归属于母公司股东的净利润 | -7,073,911.78 | 20,757,584.86 | 4,025,906.59 | -27,947,000.01 |
| 少数股东损益 | 32,378.44 | -5,036,897.54 | -4,108,816.96 | -2,772,171.36 |
| (一)基本每股收益 | -0.02 | 0.05 | 0.01 | -0.07 |
| (二)稀释每股收益 | -0.02 | 0.05 | 0.01 | -0.07 |
| 九、综合收益总额 | -7,041,533.34 | 15,720,687.32 | -82,910.37 | -30,719,171.37 |
| 归属于母公司股东的综合收益总额 | -7,073,911.78 | 20,757,584.86 | 4,025,906.59 | -27,947,000.01 |
| 归属于少数股东的综合收益总额 | 32,378.44 | -5,036,897.54 | -4,108,816.96 | -2,772,171.36 |
| 公告日期 | 2025-04-26 | 2025-03-29 | 2024-10-30 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |